Endothelin receptor antagonist activity and selective blocking the ETA and ETB of compound 0213

Journal of China Pharmaceutical University

Volumn 35, Issue 6, 2004, Pages 552-557

  Dai, De Zai ^a   Huang, Min ^a   Ji, Min ^a   Liu, Li Gang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bronchial smooth muscle; Endothelin receptor antagonists; Endothelin receptor subtype; Myocardium; Radio receptor assay; Vascular smooth muscle

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; SARAFOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GUINEA PIG; HEART MUSCLE; HEART MUSCLE FIBER MEMBRANE; MALE; NONHUMAN; PROTEIN BINDING; RAT; SMOOTH MUSCLE; STRUCTURE ANALYSIS; THORACIC AORTA;

EID: 13844266233     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells [J]. Nature, 1988, 31(6163):411-415.
2. Fang FZ, Wang ZZ, Wang SK, et al. Effect of drug on mRNA expression of voltage-gated potassium channels in myocardial remodeling by chronic L-thyroxin administration in rats [J]. Drug Develop Res, 2002, 55(4):13-19.
3. Miyuachi T, Goto K. Heart failure and endothelin receptor antagonists [J]. TIPS, 1999, 20(5):210-217.
4. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist [J]. J Pharmacol Exp Ther, 1994, 270(1):228-235.
5. Boffa JJ, Tharaux PL, Dussaule JC, et al. Regression of renal vascular fibrosis by endothelin receptor antagonism [J]. Hypertension, 2001, 37(Part 2):490-496.
6. Ellahham SH, Charlon V, Abassi Z, et al. Bosentan and the endothelin system in congestive heart failure [J]. Clin Cardiol 2000, 23(11):803-807.
7. Sam F, Colucci WS. Role of endothelin-1 in myocardial failure [J]. Proc Assoc Am Physicians, 1999, 111(5):417-422.
8. Huang M, Qi JS, He HJ, et al. Long term treatment with the novel non-peptide endothelin receptor antagonist 0213 in rats with chronic heart failure [J]. Drug Develop Res, 2002, 55(4):P24.
9. Schiffrin EL. State-of-the-Art lecture. Role of endothelin-1 in hypertension [J]. Hypertension, 1999, 34(Part 2):876-881.
10. Elijovich F, Laffer CL, Amador E, et al. Regulation of plasma endothelin by salt in salt-sensitive hypertension [J]. Circulation, 2001, 16(2):263-268.
11. Ray A, Hegde LG, Chugh A, et al. Endothelin-receptor antagonists: current and future perspectives [J]. Drug Discov Today 2000, 5 (10):455-464.
12. Clozel M. Endothelin receptor antagonists: current status and perspectives [J]. J Cardiovasc Pharmacol, 2000, 35 (Suppl 2): 65-68.
13. Feener EP, King GL. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease [J]. Heart Fail Monit, 2001, 1(3):74-82.
14. Egidy G, Juillerat-Jeanneret L, Jeannin JF, et al. Modulation of human colon tumor-stromal interactions by the endothelin system [J]. Am J Pathol, 2000, 157(6):1863-1874.
15. Dai DZ, Lin J, Wang LY, et al. The M-receptor antagonism of a new cholinolytic compound TBBB in comparison with hyoscine bromide (HBB) and atropine [J]. Act Pharmaceut Sin, 1986, 21 (11): 853-856.
16. Dai DZ, Dai Y, Wang LY, et al. The comparison of affinity between bunitrolol and propranolol to myocardial β-adrenergic receptors [J]. Bull Chin Pharmacol, 1987, 3(6):329-331.
17. Guimaraes CL, Trentin PG, Rae GA. Endothelin ET (B) receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice [J]. Clin Sci (Lond), 2002, 103(48):340S-344S.
18. Maczewski M, Beresewicz A. The role of endothelin, protein kinase C and free radicals in the mechanism of the post-ischemic endothelial dysfunction in guinea-pig hearts [J]. J Mol Cell Cardiol 2000, 32 (2):297-310.
19. Huang M, Ji M, He LS, et al. The endothelin receptor antagonist 0213 reduces L-thyroxin cardiac hypertrophy and inhibits calcium mobilization in vascular smooth muscle contraction [J]. Drug Develop Res, 2002, 55(4):P4.
20. Lambert G, Lambert E, Fassot C, et al. Subarachnoid haemorrhage-induced sympatho-excitation in rats is reversed by bosentan or sodium nitroprusside [J]. Clin Exp Pharmacol Physiol, 2001, 28(3):200-205.
21. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs [J]. Circulation, 2000, 102 (19):2434-2440.